The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical stage IV. Based on echocardiography and computed tomography there were pulmonary hypertension in course of lymphangiosis carcinomatosa as well as diffuse metastases in the abdomen diagnosed. Before the treatment initiation the patient was classified 3 in WHO performance status. After an improvement in control of the rhythm frequency and the heart failure treatment stabilisation with a β-blocker, an ACE-inhibitor, spironolactone and furosemide, the patient's performance status improved to WHO 2. He was further disqualified from surgical procedures due to the advanced clinical stage of the oncological disease. Considering high probability of further cardiotoxic influence of sorafenib on the heart failure despite its satisfactory control, the patient was assigned to palliative chemotherapy with FOLFOX. Parallel he was strictly followed up cardiologically in an outpatient clinic what certainly supported the oncological treatment. The patient survived 32 weeks from the first hospitalization and the progression free survival was 12 weeks from the chemotherapy initiation.
INTRODUCTION
This paper discusses interdisciplinary decisions regarding diagnostic and therapeutic procedures in the management of cancer and heart disease in a 75-year old patient diagnosed with de novo NYHA class III heart failure, persistent atrial fibrillation and bilateral pneumonia, and suspected of hepatocellular carcinoma (HCC) during his stay in hospital in the department of internal medicine.
CASE PRESENTATION
A 75-year old male patient, with no significant pre-existing conditions, was admitted to hospital due to fatigue, dyspnoea and oedema in calves, all of which had been increasing for several weeks. Based on a physical exam, the following was established: the patient's WHO performance status was 3 and he had an irregular heart rate of 100-120 per minute, a tendency towards hypotension, signs of bilateral pulmonary haemostasis, oedema in calves and mild ascites. A chest X-ray image showed parenchymal densities (Fig. 1 ). An abdominal ultrasound scan revealed a heterogeneous lesion measuring over 7 cm in segment IV of the liver and a number of smaller hepatic lesions measuring between 2 cm and 3 cm. Based on a computer tomography (CT) scan, pathological lesions were identified in the liver suggestive of HCC (the largest one measuring approx. 7.8 cm), and signs of cirrhotic liver and ascites were observed (Fig. 2) . Laboratory tests showed a normal level of alpha-fetoprotein, NT-pro-BNP > 2500 pg/ml, D-dimer > 2700 ng/ml, ESR of 65 mm/h, hypoalbuminemia and a positive result for anti-HCV antibodies. An ECG identified atrial fibrillation with QRS 100-120 per minute and a right bundle branch block (Fig. 3) . The patient was diagnosed with atrial fibrillation with a rapid ventricular response, de novo NYHA class III heart failure and pneumonia, and suspected of hepatocellular carcinoma associated with a hepatitis C virus (HCV) infection. The patient was started on an empiric antibiotic therapy based on amoxicillin and clavulanic acid. In order to manage the heart failure, carvedilol, ramipril and furosemide were initiated. In addition, spironolactone was given to the patient to manage the co-existing liver failure (class B according to the Child-Pugh score). The decision was taken to initiate an anticoagulant therapy based on enoxaparin at 1.5 mg per kilogram of body weight. The therapy improved the patient's overall health status, helped to control the heart rate and reduced dyspnoea and oedema in calves. Echocardiography showed signs of pulmonary hypertension with right ventricular systolic pressure (RVSP) at 65-70 mmHg, a dilated and non-reactive inferior vena cava, a slightly dilated pulmonary trunk (27 mm) and both pulmonary arteries, boundary PAccT at Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III "de novo" M. Żechowicz does not improve the prognosis, either [11] . Sorafenib turned out to be the only drug which slightly improves survival of HCC patients. However, its use is associated with cardiotoxicity whose severity and extent has not been yet fully researched [7, 13] . The prognosis for inoperable HCC is poor, with 5-year survival occurring in only up to 10% of cases and median survival of merely ca. 12-16 weeks [2, 3] . Similarly, prognosis for patients with advanced heart failure is poor, and only approx. 50%
of them survive 24 months [4] . Currently, it may be assumed that a patient with a heart failure, diagnosed and treated, is at a higher risk of developing cancer in the future, with the risk increasing along with the duration of heart failure treatment [15] . survival by up to 44% [14] as compared to cytotoxic treatment based on doxorubicin or cisplatin (positive response to therapy < 10%) [11] . 10% of patients treated with sorafenib experience a decrease in ejection fraction, and either develop heart failure symptoms or their existing symptoms are exacerbated [7, 13] .
Selection of the safest possible anticoagulant agent to manage atrial fibrillation proved difficult given that cancer patients are not recommended to receive novel oral anticoagulants (such as rivaroxaban and dabigatran). In addition, it was difficult to maintain a therapeutic INR level during warfarin therapy due to co-existence of a liver disease with malignant tumours [8, 9] .
Eventually, the patient was given therapeutic doses of enoxaparin and did not suffer haemorrhagic complications or thromboembolic events. Despite the poor prognosis at the outset and no proof that the systemic treatment regimen improves survival [10, 11] , the patient survived a total of 32 weeks after the first hospital admission in a quite good clinical status and mental condition. It seems that the β-blocker and ACE-I, used not only to manage the heart failure but also to protect the heart from impact of the cancer therapy [17] , had a beneficial effect 
